Zylera Pharmaceuticals
Zylera is focused on developing medications that will treat multiple diseases arising within the inflammation and immunosuppressive pathways. Its near-term pipeline includes products for diabetes, elevated cholesterol, osteoporosis, and osteoarthritis, utilizing proprietary and patented chemical entities designed to restore key metabolic processes. Chief among these is Cytac™, a carbonyl-trapping agent. Zylera is a wholly owned subsidiary of TRx Pharma and is based in Research Triangle Park, NC.